Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific completes Taxus trial enrolment

Boston Scientific completes Taxus trial enrolment

9th October 2008

Boston Scientific has announced the completion of its clinical trial enrolment for its Perseus clinical programme to evaluate its third-generation drug-eluting Taxus Element platinum chromium stent.

The company said it had enrolled almost 1,500 patients at 100 centres since July 2007.

Patients in the trial will be tested with either the Taxus Element stent or the prior-generation Taxus Expres2 Stent which has been on the market since 2004.

The firm said it hopes to develop further versions of the Element platform, including an everolimus-eluting Promus Element stent system and next-generation bare metal stents.

Keith Dawkins, senior vice-president and associate chief medical officer for Boston Scientific, said: “We are pleased to reach this important milestone in the development of our third-generation drug-eluting stent, at a time when most companies are still introducing their first-generation stents in the US.”

He added the company is the only one to offer interventionalists a choice between two different drugs in a single drug-eluting stent platform.

Last month, Boston Scientific announced the results of its Syntax trial assessing safety outcomes for complex patients treated with the Taxus Express2 stent and bypass surgery, with comparable safety outcomes shown in both groups.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.